An article from The Washington Times examines the motivations behind the cannabis industry, suggesting that financial gain often takes precedence over medicinal benefits. Critics argue that despite claims of therapeutic uses, the primary driver for many companies is the substantial profit potential. This focus on revenue has led to aggressive marketing and lobbying efforts to expand legalisation and increase market share.

The report also highlights concerns that the emphasis on profit may overshadow important health considerations and regulatory oversight. Advocates for tighter controls worry that without stricter regulations and a more balanced approach, the negative consequences could outweigh the purported medicinal advantages.

Source: The Washington Times